Phase 2: Impact of Lipoic Acid on Cystine Nephrolithiasis; IND129545 (01/29/2016)

第二阶段：硫辛酸对胱氨酸肾结石的影响；

• 批准号: 10381461
• 负责人: Tom Chi
• 金额: $ 50万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-04-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10381461
• 关键词: Phase; Impact; Lipoic; Acid; Cystine

PROJECT ABSTRACT Cystinuria is a rare (1:15,000) autosomal recessive disease characterized by markedly elevated levels of urinary cystine, and recurrent episodes of painful, tissue damaging kidney stone formation. There is no successful medical management of this disorder and even though patients may receive temporary relief through surgical intervention, the period of remission is typically brief and they have a higher risk of end-stage renal disease over time. We propose a novel treatment for cystinuria, to be tested in a Phase 2 randomized double-blind, placebo- controlled clinical trial to assess the impact of alpha-lipoic acid (lipoic acid) on cystine stone growth and recurrence, and need for surgical intervention. Using a mouse model of cystinuria, we have found that this widely used, well tolerated and naturally occurring dietary supplement, both prevents the onset of cystine stone formation and slows the growth of existing stones. These results dramatically overshadow the minimal action of existing pharmaceuticals tested in the same murine model and used in humans to treat cystinuria. In this mouse cystinuria model lipoic acid-supplemented diets did not impact mice weight, water consumption or activity levels. These promising murine data inspired this human trial. We propose a randomized double-blind placebo-controlled trial enrolling 50 cystinuric patients from our established clinical stone center (>30 years) that will facilitate rapid enrollment. The design will assess how daily 1200 mg of lipoic acid supplementation for three years will impact clinical outcomes. Outcome measures will include: 1) clinical progression of disease, marked by stone recurrence based on routine imaging, quality of life measurement, stone passage, and/or the need for surgical intervention; 2) quantitative urinary cystine levels and cystine solubility on traditional 24-hour urine collection; and 3) metabolomic and metallomic analyses of stone and urine samples. As per normal, routine clinical care, study participants will be seen every 4 months for comprehensive clinical evaluation including serum labs, imaging, and 24-hour urine studies. In addition to clinical data, stone, urine, and blood samples will be collected over the study to determine metabolomic and metallomic profiles and urinary cystine solubility, to identify biomarkers to help predict treatment effect and to form the basis of personalized medicine for patients with this rare disease. These latter measures represent an effort to identify readily available predictive makers of stone initiation and formation (none of which exist at the present time), and provide insight into the possible mechanism of action of lipoic acid. If successful, the use of lipoic acid will radically change the health and life- styles of patients with cystinuria, a rare, orphan and debilitating disease. Furthermore, the study of appropriate metabolomics and metallomic biomarkers for cystinuria may also yield important insights into other types of urinary stones.

项目摘要

项目成果

A Drosophila model identifies a critical role for zinc in mineralization for kidney stone disease.

果蝇模型确定了锌在肾脏疾病的矿化中的关键作用。

• DOI: 10.1371/journal.pone.0124150
• 发表时间: 2015
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Chi T;Kim MS;Lang S;Bose N;Kahn A;Flechner L;Blaschko SD;Zee T;Muteliefu G;Bond N;Kolipinski M;Fakra SC;Mandel N;Miller J;Ramanathan A;Killilea DW;Brückner K;Kapahi P;Stoller ML
• 通讯作者: Stoller ML